Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics (FBLG) is a Houston-based clinical-stage biotechnology company pioneering fibroblast cell therapies for chronic diseases like cancer, multiple sclerosis, and wound healing. This page serves as the definitive source for verified news, press releases, and clinical updates directly from FibroBiologics and trusted partners.
Investors and researchers will find timely updates on clinical trial progress, patent developments, and strategic collaborations with organizations like Charles River. Content spans FDA submissions, manufacturing advancements, and scientific breakthroughs in regenerative medicine.
All materials are curated for accuracy and relevance, providing stakeholders with actionable insights into FBLG’s pipeline and market position. Bookmark this page or check back regularly to stay informed about fibroblast therapy innovations shaping modern medicine.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation at The Cell & Gene Meeting On The Mediterranean in Rome from April 15-17, 2025. The company's Chief Scientific Officer, Dr. Hamid Khoja, will present on their innovative fibroblast cell-based therapeutic approach for chronic diseases.
The presentation, titled 'Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases,' will take place on Wednesday, April 16 at 9:00 AM CEST at the Salone dei Cavalieri.
FibroBiologics specializes in developing treatments using fibroblast cells and fibroblast-derived materials, with a significant intellectual property portfolio of 240+ US and international patents. Their research spans multiple therapeutic areas including:
- Wound healing
- Multiple sclerosis
- Disc degeneration
- Psoriasis
- Orthopedics
- Human longevity
- Cancer
FibroBiologics (Nasdaq: FBLG) has announced the opening of a new laboratory facility in Houston, Texas, marking a significant expansion of its research capabilities in fibroblast-based therapeutics. The new facility spans over 10,000 square feet of lab and office space, designed to accelerate the development of treatments for chronic diseases.
The expansion will enable the company to:
- Increase the pace of discovery for potential therapeutics
- Enhance development of treatment candidates
- Potentially bring GMP manufacturing in-house for drug product candidates
- Hire additional researchers
The company, which holds 240+ patents issued and pending, aims to streamline its supply chain and reduce reliance on external partners through this expansion. The facility will allow for broader pipeline exploration and more effective collaboration in developing fibroblast-based technology.
FibroBiologics (Nasdaq: FBLG) has announced a breakthrough in neurodegenerative disease research through their Cuprizone animal model study. The research demonstrated that intravenous fibroblasts can significantly increase myelin expression within seven weeks using both single and multiple dose treatments.
This finding confirms their previous results from the Experimental Autoimmune Encephalomyelitis (EAE) animal model. The research focuses on myelin sheath regeneration, which is important for proper nerve function and often damaged in conditions like multiple sclerosis. The myelin sheath is essential for rapid neural communication, affecting functions such as thinking, memory, movement, and coordination.
The company, which holds 240+ patents issued and pending for fibroblast-based therapeutics, aims to develop treatments that address the root causes of chronic diseases rather than just symptoms.
FibroBiologics (NASDAQ: FBLG) has reported its full year 2024 financial results and corporate updates. The company completed its proprietary master cell bank for CYWC628, their fibroblast-based spheroids product candidate for diabetic foot ulcers (DFUs), meeting Good Manufacturing Practices requirements.
Key financial highlights include:
- Cash position of $14.0 million as of December 31, 2024
- R&D expenses increased to $4.5 million from $2.4 million in 2023
- G&A expenses rose to $9.2 million from $6.5 million in 2023
- Net loss decreased to $11.2 million compared to $16.5 million in 2023
The company secured a $25.0 million Standby Equity Purchase Agreement with Yorkville, with $10.0 million already advanced. FibroBiologics plans to initiate a Phase 1/2 clinical trial for CYWC628 in Australia during Q2 2025, with completion expected by year-end.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, has announced its 2025 Annual Meeting of Stockholders, scheduled for June 12, 2025, at 11 a.m. CDT. The meeting will be held exclusively in a virtual format.
The company, which focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has set April 14, 2025 as the record date for stockholder voting eligibility. FibroBiologics currently maintains a portfolio of 160+ US and international patents/patents pending across various clinical pathways, including:
- Disc degeneration
- Orthopedics
- Multiple sclerosis
- Psoriasis
- Wound healing
- Reversing organ involution
- Cancer
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced its participation at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany (March 26-28, 2025). Dr. Hamid Khoja, Chief Scientific Officer, will present on the company's fibroblast cell-based approach for treating chronic diseases.
The presentation, titled 'Potential Treatment of Chronic Diseases With the Aim of Immune System Homeostasis Rather Than Depletion or Over-activation', will take place on March 27, 2025, from 10:25 a.m. to 12:00 p.m. Central European Time at Otto-Krayer Haus.
FibroBiologics specializes in developing therapeutics using fibroblasts and fibroblast-derived materials, with applications across multiple conditions including:
- Disc degeneration
- Orthopedics
- Multiple sclerosis
- Psoriasis
- Wound healing
- Organ involution reversal
- Cancer
FibroBiologics (Nasdaq: FBLG) has filed a patent application for a novel method using fibroblasts to improve mitochondrial performance in cells. The company, which holds 160+ patents, is developing this innovative approach to potentially treat chronic conditions driven by mitochondrial dysregulation.
The technology leverages fibroblasts' natural ability to secrete bioactive molecules that influence cellular microenvironments. Through local or systemic fibroblast administration, this method aims to address mitochondrial dysfunction, which is implicated in aging, autoimmune, neurodegenerative, metabolic, and muscular diseases.
The patent filing represents a potential breakthrough in treating chronic diseases by modulating mitochondrial activity, which could fundamentally alter treatment approaches and impact human longevity.
FibroBiologics (Nasdaq: FBLG) and Charles River Laboratories have announced the completion of a master cell bank for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers. The cell bank, manufactured under FDA Good Manufacturing Practices (cGMP), has passed all required safety testing.
The master cell bank will support upcoming phase I/II clinical trials for diabetic foot ulcers scheduled to begin in 2025. Charles River's cGMP manufacturing facilities will produce both the cell banks and drug product for the trials.
FibroBiologics, a clinical-stage biotech company with 160+ patents issued and pending, focuses on developing therapeutics using fibroblasts and fibroblast-derived materials. Their research spans multiple indications including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, human longevity, and cancer.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focusing on fibroblast-based therapeutics for chronic diseases, has announced two significant upcoming events. The company will host an in-person analyst day on February 12, 2025, at 2:00 p.m. ET at the New York Marriott Marquis.
The analyst day will feature presentations from key management members, including CEO Pete O'Heeron, CSO Hamid Khoja, PhD, and Interim CFO Robert Hoffman. The event will showcase the company's research and development strategy for fibroblast-based therapeutics, followed by a live Q&A session.
Additionally, FibroBiologics will present at the 2025 BIO CEO & Investor Conference in New York on February 11 at 11:15 a.m. ET. The presentation will take place in the Plymouth Room at the New York Marriott Marquis.
FibroBiologics (NASDAQ: FBLG) has closed the second $5 million tranche of its previously announced $25 million Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The agreement allows FibroBiologics to sell up to $25 million of common stock over two years, with the first $15 million being advanced in three equal tranches via convertible promissory notes.
The first $5 million tranche was funded upon SEPA entry, and the second $5 million followed the filing of a registration statement. The third $5 million will be funded after registration statement effectiveness and Nasdaq-required shareholder approval. An additional $10 million can be sold subject to Yorkville's consent while the notes remain outstanding.
